Publications by authors named "Yuanxia Gu"
Unlabelled: Previous studies have profiled the gut microbiota among psoriatic patients compared to that among healthy individuals. However, a comprehensive understanding of the magnitude, direction, and detailed compositional and functional profiles remains limited. Additionally, research exploring the gut microbiota in the context of both plaque psoriasis (PsO) and psoriatic arthritis (PsA) is lacking.
View Article and Find Full Text PDFIntroduction: The utilization of biologics in patients with psoriasis with latent tuberculosis infection (LTBI) has garnered significant attention. Although the tuberculosis (TB) safety profile of second-generation biologics, including secukinumab, has been partially confirmed in both clinical trials and real-world studies, the necessity for prophylactic therapy in patients with LTBI prior to administering this class of biologics remains a topic of controversy.
Methods: This study enrolled 62 patients with psoriasis with LTBI who underwent secukinumab with routine TB reexamination.
Introduction: This study aims to describe the demographic, clinical, laboratory, and ultrasonic characteristics of patients with psoriatic arthritis (PsA) in the Psoriatic Arthritis cohort of West China Hospital.
Methods: In this cross-sectional study, we included patients diagnosed with PsA according to the Classification Criteria for Psoriatic Arthritis, collected their demographic information, medical histories, and treatments, evaluated all domains (skin and nail lesions, tenderness, swelling, enthesitis, dactylitis, and axial arthritis) related to PsA, and then performed descriptive statistical analyses of all data.
Results: A total of 275 patients with PsA were included in this study.
Article Synopsis
- A study was conducted in China to evaluate the effectiveness and safety of two biologics, adalimumab (ADA) and secukinumab (SEC), for treating moderate-to-severe plaque psoriasis, amidst a rise in their usage due to new insurance coverage.
- The results showed that SEC led to a higher reduction in psoriasis severity compared to ADA and methotrexate after 12 weeks, although adverse events were reported in a significant number of patients for both treatments.
- Cost-effectiveness analysis revealed that while ADA was more cost-effective based on drug prices, both treatments were deemed effective and safe for patients in real-world settings.
Article Synopsis
- * Among adalimumab patients, 5.43% experienced TB conversion with two developing active TB, while 5.26% of secukinumab patients had positive TB conversions but none progressed to active TB.
- * Findings indicate a significant TB conversion rate after an average of 17 months of treatment, leading to recommendations for monitoring: more frequent assessments for adalimumab patients and annual check-ups for those on secukinumab.
Introduction: This study aimed to develop a predictive model based on ultrasound variables which can be used to screen patients with psoriasis who are prone to progress to psoriatic arthritis (PsA) in clinical practice.
Methods: This is a cross-sectional study conducted in a single center from October 2018 to November 2020. All subjects (non-PsA group, PsA group, and control group) underwent an ultrasound examination and their ultrasound abnormalities were recorded.
Azathioprine (AZA) is the preferred immunosuppressant for treating pemphigus vulgaris (PV), with discontinuation mainly attributed to hematological adverse events (AE). Reportedly, nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) polymorphisms have been strongly associated with thiopurine-induced leukopenia. To investigate hematological AE of low-dose AZA based on NUDT15 genotypes among patients with PV, a prospective cohort study was conducted in patients with PV, followed-up for the first 8 weeks after AZA administration.
View Article and Find Full Text PDFIntroduction: The objective of this study is to identify the potential risk factors for progression from subclinical to clinical psoriatic arthritis (PsA).
Methods: A retrospective, longitudinal, case-control study was conducted at a single hospital, including 25 patients with clinically confirmed PsA in the case group and 137 controls without confirmed PsA. All patients in both groups had a medical history of subclinical PsA.